Print Page   Close Window

Press Release

POZEN Announces Completion of Special Protocol Assessment for PN 200; New Arthritis Product Phase III Trials to Begin on Schedule

CHAPEL HILL, N.C.--(BUSINESS WIRE)--April 20, 2006--POZEN Inc. (NASDAQ: POZN) announced today that it has completed a Special Protocol Assessment (SPA) and reached agreement with the U.S. Food and Drug Administration (FDA) on the design of its pivotal trials for PN 200. PN 200 is a product candidate for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk for developing NSAID-associated gastric ulcers. The SPA is a process by which the FDA provides evaluation and guidance on proposed protocols for clinical trials.

Dr. Marshall E. Reese, executive vice president, product development, commented, "We are very pleased to have reached agreement with the FDA on the design of these pivotal clinical trials. We expect to move forward as planned with the initiation of our Phase III program within the next few months."

About PN

PN 200 is a combination of an acid inhibitor, e.g., proton pump inhibitor (PPI) with a non-steroidal anti-inflammatory drug (NSAID) in a single tablet. The product is intended to manage pain and inflammation with fewer gastrointestinal side effects and less gastric damage, including ulcers, compared to an NSAID taken alone.


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of acute and chronic pain, migraine, and other pain-related conditions. POZEN has a development and commercialization alliance with GlaxoSmithKline. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Annual Report on Form 10-K for the period ended December 31, 2005. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Bill Hodges, 919-913-1030
Chief Financial Officer
Fran Barsky, 919-913-1044
Director, Investor Relations